Free Trial
→ $100 Trillion “AI Metal” Found in American Ghost Town (From Brownstone Research) (Ad) Free NTLA Stock Alerts

Intellia Therapeutics (NTLA) Financials

Intellia Therapeutics logo
$12.10 +0.62 (+5.36%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Intellia Therapeutics

Annual Income Statements for Intellia Therapeutics

This table shows Intellia Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -12 -32 -68 -85 -100 -134 -268 -474 -481 -519
Consolidated Net Income / (Loss)		 -12 -32 -68 -85 -100 -134 -268 -474 -481 -519
Net Income / (Loss) Continuing Operations		 -12 -32 -68 -85 -99 -134 -270 -474 -477 -518
Total Pre-Tax Income 		-13 -32 -68 -85 -99 -134 -270 -474 -477 -518
Total Operating Income		 -13 -32 -70 -91 -106 -137 -268 -458 -515 -534
Total Gross Profit		 6.04 16 26 30 43 58 33 52 36 58
Total Revenue		 6.04 16 26 30 43 58 33 52 36 58
Operating Revenue		 6.04 16 26 30 43 58 33 52 36 58
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 19 49 96 121 149 195 301 510 552 592
Selling, General & Admin Expense		 8.28 17 28 32 41 44 71 90 116 126
Research & Development Expense		 11 32 68 89 108 150 230 420 435 466
Other Special Charges / (Income)		 - - - - - 0.00 0.00 - 0.10 0.00
Total Other Income / (Expense), net		 0.00 0.53 2.01 5.50 7.12 2.35 -2.21 -16 38 16
Interest & Investment Income		 0.00 0.53 2.01 5.53 6.84 2.35 -0.04 -2.54 34 15
Other Income / (Expense), net		 - 0.00 0.00 -0.03 0.29 0.00 -2.17 -13 3.64 0.73
Basic Earnings per Share		 ($51.02) ($1.42) ($1.88) ($1.98) ($2.11) ($2.40) ($3.78) ($6.16) ($5.42) ($5.25)
Weighted Average Basic Shares Outstanding		 243K 22.22M 36.01M 43.07M 47.25M 55.99M 70.89M 76.97M 88.77M 98.85M
Diluted Earnings per Share		 ($51.02) ($1.42) ($1.88) ($1.98) ($2.11) ($2.40) ($3.78) ($6.16) ($5.42) ($5.25)
Weighted Average Diluted Shares Outstanding		 243K 22.22M 36.01M 43.07M 47.25M 55.99M 70.89M 76.97M 88.77M 98.85M
Weighted Average Basic & Diluted Shares Outstanding		 243K 22.22M 36.01M 43.07M 47.25M 55.99M 70.89M 88.02M 96.11M 103.52M

Quarterly Income Statements for Intellia Therapeutics

This table shows Intellia Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -113 -113 -103 -124 -122 -132 -107 -147 -136 -129 -114
Consolidated Net Income / (Loss)		 -113 -113 -103 -124 -122 -132 -107 -147 -136 -129 -114
Net Income / (Loss) Continuing Operations		 -113 -113 -103 -125 -122 -128 -108 -147 -136 -128 -114
Total Pre-Tax Income 		-113 -113 -103 -125 -122 -128 -108 -147 -136 -128 -114
Total Operating Income		 -106 -110 -112 -132 -131 -140 -114 -139 -145 -136 -121
Total Gross Profit		 13 14 13 14 12 -1.92 29 6.96 9.11 13 17
Total Revenue		 13 14 13 14 12 -1.92 29 6.96 9.11 13 17
Operating Revenue		 13 14 13 14 12 -1.92 29 6.96 9.11 13 17
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 119 123 125 146 143 138 143 146 154 149 137
Selling, General & Admin Expense		 22 24 27 31 29 29 31 32 31 32 29
Research & Development Expense		 97 100 97 115 114 109 112 114 123 117 108
Total Other Income / (Expense), net		 -7.70 -2.71 8.83 7.46 9.18 12 5.75 -8.14 9.06 8.49 6.93
Interest & Investment Income		 0.11 2.11 8.93 8.65 8.88 7.73 6.57 -7.93 9.06 7.55 6.48
Other Income / (Expense), net		 -7.81 -4.81 -0.10 -1.19 0.30 4.63 -0.82 -0.21 0.00 0.94 0.45
Basic Earnings per Share		 ($1.49) ($1.38) ($1.17) ($1.40) ($1.38) ($1.47) ($1.12) ($1.52) ($1.34) ($1.27) ($1.10)
Weighted Average Basic Shares Outstanding		 76.05M 76.97M 87.77M 88.19M 88.65M 88.77M 95.50M 96.98M 101.00M 98.85M 103.50M
Diluted Earnings per Share		 ($1.49) ($1.38) ($1.17) ($1.40) ($1.38) ($1.47) ($1.12) ($1.52) ($1.34) ($1.27) ($1.10)
Weighted Average Diluted Shares Outstanding		 76.05M 76.97M 87.77M 88.19M 88.65M 88.77M 95.50M 96.98M 101.00M 98.85M 103.50M
Weighted Average Basic & Diluted Shares Outstanding		 78.68M 88.02M 88.14M 88.49M 89.55M 96.11M 96.48M 101.58M 101.85M 103.52M 103.58M

Annual Cash Flow Statements for Intellia Therapeutics

This table details how cash moves in and out of Intellia Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 66 197 68 -282 5.82 107 -39 410 -295 -38
Net Cash From Operating Activities		 -1.76 36 -65 -61 -103 -50 -225 -333 -394 -349
Net Cash From Continuing Operating Activities		 -1.76 36 -65 -61 -96 -50 -225 -333 -394 -349
Net Income / (Loss) Continuing Operations		 -12 -32 -68 -85 -100 -134 -268 -474 -481 -519
Consolidated Net Income / (Loss)		 -12 -32 -68 -85 -100 -134 -268 -474 -481 -519
Depreciation Expense		 0.33 1.10 2.99 4.46 5.59 6.31 6.89 7.57 8.98 10
Amortization Expense		 - 0.00 0.00 -0.68 3.73 0.54 7.60 4.00 -26 -18
Non-Cash Adjustments To Reconcile Net Income		 1.32 6.73 15 17 21 26 61 183 175 187
Changes in Operating Assets and Liabilities, net		 8.99 60 -16 3.18 -26 51 -32 -54 -71 -9.59
Net Cash From Investing Activities		 -2.55 -6.17 -10 -261 25 -214 -551 160 -31 126
Net Cash From Continuing Investing Activities		 -2.55 -6.17 -10 -261 25 -214 -551 160 -31 126
Purchase of Property, Plant & Equipment		 -2.55 -6.17 -10 -6.36 -6.79 -3.59 -13 -14 -14 -5.78
Acquisitions		 - - - - - - 0.00 -45 0.00 0.00
Purchase of Investments		 - 0.00 0.00 -255 -297 -474 -1,021 -429 -904 -936
Sale of Property, Plant & Equipment		 - 0.00 0.00 0.13 0.00 0.00 0.00 0.15 0.00 0.00
Sale and/or Maturity of Investments		 - - 0.00 0.00 329 263 486 648 887 1,067
Net Cash From Financing Activities		 70 167 143 40 76 372 737 583 130 186
Net Cash From Continuing Financing Activities		 70 167 143 40 76 372 737 583 130 186
Issuance of Common Equity		 0.00 171 142 30 73 360 696 568 124 180
Other Financing Activities, net		 -1.10 -0.60 1.16 11 3.09 12 41 15 6.60 5.86

Quarterly Cash Flow Statements for Intellia Therapeutics

This table details how cash moves in and out of Intellia Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -6.91 386 -229 -122 -2.78 59 -55 -41 -10 69 -55
Net Cash From Operating Activities		 -79 -90 -109 -90 -101 -93 -121 -58 -85 -85 -149
Net Cash From Continuing Operating Activities		 -79 -90 -109 -90 -101 -93 -121 -58 -85 -85 -149
Net Income / (Loss) Continuing Operations		 -113 -113 -103 -124 -122 -132 -107 -147 -136 -129 -114
Consolidated Net Income / (Loss)		 -113 -113 -103 -124 -122 -132 -107 -147 -136 -129 -114
Depreciation Expense		 1.95 2.03 2.05 2.17 2.29 2.47 2.51 2.60 2.61 2.57 2.50
Amortization Expense		 0.82 -1.25 -4.57 -7.10 -7.92 -6.31 -5.29 -4.65 -4.28 -3.60 -2.28
Non-Cash Adjustments To Reconcile Net Income		 33 35 38 48 45 45 24 66 48 49 31
Changes in Operating Assets and Liabilities, net		 -0.98 -13 -41 -9.69 -18 -1.75 -35 25 4.86 -4.38 -66
Net Cash From Investing Activities		 48 -30 -122 -35 80 46 5.90 -24 -7.71 152 94
Net Cash From Continuing Investing Activities		 48 -30 -122 -35 80 46 5.90 -24 -7.71 152 94
Purchase of Property, Plant & Equipment		 -4.24 -3.91 -3.83 -4.30 -4.33 -1.52 -2.51 -1.01 -1.28 -0.98 -0.74
Purchase of Investments		 -161 -236 -382 -243 -129 -150 -260 -301 -206 -169 -83
Sale and/or Maturity of Investments		 213 210 264 213 213 197 268 278 200 322 178
Net Cash From Financing Activities		 24 506 2.22 2.52 19 106 60 41 82 2.32 0.00
Net Cash From Continuing Financing Activities		 24 506 2.22 2.52 19 106 60 41 82 2.32 0.00
Issuance of Common Equity		 23 505 1.47 2.05 15 105 58 40 80 1.29 0.00
Other Financing Activities, net		 0.72 0.53 0.76 0.47 4.38 1.00 1.96 1.18 1.70 1.03 0.00

Annual Balance Sheets for Intellia Therapeutics

This table presents Intellia Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 82 299 376 347 334 676 1,294 1,520 1,301 1,191
Total Current Assets		 78 281 355 325 289 617 769 1,217 998 640
Cash & Equivalents		 76 273 341 59 57 160 123 524 227 189
Short-Term Investments		 - - 0.00 255 223 437 625 669 685 412
Accounts Receivable		 1.00 6.45 10 7.55 4.62 2.13 2.03 3.77 36 8.52
Prepaid Expenses		 0.81 1.79 3.68 3.37 5.14 17 19 20 50 30
Plant, Property, & Equipment, net		 2.71 11 15 17 18 16 21 28 33 27
Total Noncurrent Assets		 1.81 7.04 6.13 5.28 27 44 504 275 270 524
Long-Term Investments		 - - - 0.00 4.75 4.75 425 142 155 304
Other Noncurrent Operating Assets		 1.81 7.04 6.13 5.28 22 39 79 133 115 219
Total Liabilities & Shareholders' Equity		 82 299 376 347 334 676 1,294 1,520 1,301 1,191
Total Liabilities		 15 89 76 69 64 149 254 285 251 319
Total Current Liabilities		 11 31 31 41 36 64 126 127 115 111
Accounts Payable		 1.36 4.65 2.17 2.71 3.94 10 9.65 5.15 7.45 15
Accrued Expenses		 2.79 5.90 8.00 11 13 26 43 61 67 55
Current Deferred Revenue		 6.55 20 21 27 13 23 64 44 22 21
Other Current Liabilities		 - - - 0.00 5.75 5.70 9.11 17 19 20
Total Noncurrent Liabilities		 4.09 58 44 29 29 85 128 158 136 208
Noncurrent Deferred Revenue		 3.77 58 44 29 16 51 63 20 39 18
Other Noncurrent Operating Liabilities		 0.32 0.29 0.17 0.01 13 34 65 138 97 190
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -21 210 301 278 270 527 1,040 1,236 1,050 872
Total Preferred & Common Equity		 -21 210 301 278 270 527 1,040 1,236 1,050 872
Total Common Equity		 -21 210 301 278 270 527 1,040 1,236 1,050 872
Common Stock		 0.74 263 422 479 570 962 1,746 2,420 2,711 3,049
Retained Earnings		 -22 -54 -121 -201 -301 -435 -703 -1,177 -1,658 -2,177
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 -0.03 0.26 0.00 -2.63 -7.46 -2.26 0.61

Quarterly Balance Sheets for Intellia Therapeutics

This table presents Intellia Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 1,110 1,084 1,418 1,323 1,243 1,260 1,192 1,173 986
Total Current Assets		 895 859 964 940 893 884 757 711 551
Cash & Equivalents		 148 141 294 172 168 172 131 120 127
Short-Term Investments		 726 687 639 736 687 619 560 538 377
Accounts Receivable		 2.85 4.02 4.91 5.06 6.49 36 12 8.85 11
Prepaid Expenses		 18 27 25 26 32 56 54 44 37
Plant, Property, & Equipment, net		 26 27 32 33 34 32 30 29 25
Total Noncurrent Assets		 189 199 423 350 316 343 404 434 410
Long-Term Investments		 115 98 294 227 197 233 299 333 272
Other Noncurrent Operating Assets		 74 101 128 124 119 110 105 100 138
Total Liabilities & Shareholders' Equity		 1,110 1,084 1,418 1,323 1,243 1,260 1,192 1,173 986
Total Liabilities		 230 260 227 218 206 223 220 211 206
Total Current Liabilities		 124 131 103 100 92 98 105 106 113
Accounts Payable		 7.52 4.38 6.89 12 3.55 14 19 13 12
Accrued Expenses		 45 58 45 50 58 43 45 51 41
Current Deferred Revenue		 62 55 35 22 13 22 22 22 21
Other Current Liabilities		 9.57 14 16 17 17 19 19 19 39
Total Noncurrent Liabilities		 106 128 124 119 114 126 115 105 94
Noncurrent Deferred Revenue		 35 26 14 13 13 33 28 23 13
Other Noncurrent Operating Liabilities		 71 103 110 106 101 92 87 82 80
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 881 825 1,191 1,105 1,037 1,036 971 963 780
Total Preferred & Common Equity		 881 825 1,191 1,105 1,037 1,036 971 963 780
Total Common Equity		 881 825 1,191 1,105 1,037 1,036 971 963 780
Common Stock		 1,841 1,898 2,474 2,513 2,567 2,803 2,885 3,008 3,071
Retained Earnings		 -951 -1,064 -1,280 -1,404 -1,526 -1,766 -1,913 -2,049 -2,292
Accumulated Other Comprehensive Income / (Loss)		 -9.55 -9.37 -2.68 -3.87 -3.57 -0.95 -1.16 3.30 1.06

Annual Metrics And Ratios for Intellia Therapeutics

This table displays calculated financial ratios and metrics derived from Intellia Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 172.65% 58.49% 16.53% 41.63% 34.55% -43.01% 57.69% -30.40% 59.55%
EBITDA Growth		 0.00% -137.41% -114.33% -30.87% -11.09% -34.07% -96.96% -80.05% -14.89% -2.36%
EBIT Growth		 0.00% -139.83% -116.28% -30.69% -16.70% -28.76% -97.70% -74.67% -8.48% -4.28%
NOPAT Growth		 0.00% -139.83% -116.28% -30.64% -17.06% -28.41% -96.11% -71.05% -12.47% -3.68%
Net Income Growth		 0.00% -155.17% -113.51% -26.35% -16.63% -34.86% -99.58% -77.01% -1.48% -7.86%
EPS Growth		 0.00% 97.22% -32.39% -5.32% -6.57% -13.74% -57.50% -62.96% 12.01% 3.14%
Operating Cash Flow Growth		 0.00% 2,148.16% -280.77% 6.16% -68.54% 51.65% -350.85% -48.11% -18.24% 11.47%
Free Cash Flow Firm Growth		 0.00% 0.00% -322.70% 5.96% -42.12% 63.39% -267.11% -174.98% -24.98% 19.61%
Invested Capital Growth		 0.00% -647.36% 36.61% 9.84% 59.63% -414.34% -77.88% 25.57% 83.33% -105.47%
Revenue Q/Q Growth		 0.00% 31.36% 4.15% 4.15% 7.63% -6.96% 23.36% 1.40% -29.92% 34.33%
EBITDA Q/Q Growth		 0.00% -19.46% -25.36% 4.03% -1.08% -16.71% -17.81% -8.40% -4.96% 0.85%
EBIT Q/Q Growth		 0.00% -19.87% -24.96% 4.16% -9.35% -9.92% -17.81% -7.26% -4.14% 0.34%
NOPAT Q/Q Growth		 0.00% -19.87% -24.96% 4.19% -9.27% -10.19% -16.54% -6.92% -6.14% 0.64%
Net Income Q/Q Growth		 0.00% -20.21% -24.75% 5.43% -10.20% -11.57% -17.06% -7.28% -4.06% 0.62%
EPS Q/Q Growth		 0.00% 97.04% -124.10% 9.59% -7.65% -5.26% -12.50% -4.58% -1.69% 3.67%
Operating Cash Flow Q/Q Growth		 0.00% -19.81% -11.81% 17.25% -24.21% -30.16% -6.85% -11.82% -0.81% 2.20%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -10.45% 18.44% -4.22% -143.48% 4.23% -16.91% -4.09% 1.57%
Invested Capital Q/Q Growth		 0.00% 12.78% 13.65% -20.55% -143.35% 4.19% -27.80% 1.50% -13.04% -17.97%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -216.43% -188.45% -254.86% -286.23% -224.50% -223.70% -773.07% -882.70% -1,457.14% -934.85%
Operating Margin		 -221.86% -195.15% -266.32% -298.58% -246.78% -235.51% -810.37% -879.04% -1,420.51% -923.10%
EBIT Margin		 -221.86% -195.15% -266.32% -298.67% -246.11% -235.51% -816.92% -904.91% -1,410.49% -921.84%
Profit (Net Income) Margin		 -205.11% -191.97% -258.62% -280.42% -230.92% -231.46% -810.49% -909.78% -1,326.51% -896.77%
Tax Burden Percent		 92.45% 100.00% 100.00% 99.97% 100.29% 100.00% 99.20% 100.00% 100.78% 100.14%
Interest Burden Percent		 100.00% 98.37% 97.11% 93.92% 93.56% 98.28% 100.02% 100.54% 93.32% 97.14%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -18.41% -22.82% -26.46% -29.50% -36.34% -33.69% -34.18% -41.67% -42.10% -54.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -16.32% -16.88% -20.60% -25.13% -31.13% -27.03% -27.40% -33.51% -36.27% -42.82%
Return on Assets (ROA)		 -15.09% -16.60% -20.01% -23.59% -29.21% -26.56% -27.19% -33.70% -34.11% -41.66%
Return on Common Equity (ROCE)		 5.79% -15.53% -26.46% -29.50% -36.34% -33.69% -34.18% -41.67% -42.10% -54.00%
Return on Equity Simple (ROE_SIMPLE)		 58.47% -15.08% -22.47% -30.71% -36.88% -25.47% -25.75% -38.38% -45.82% -59.52%
Net Operating Profit after Tax (NOPAT)		 -9.39 -23 -49 -64 -74 -96 -187 -321 -361 -374
NOPAT Margin		 -155.30% -136.61% -186.42% -209.01% -172.74% -164.86% -567.26% -615.33% -994.36% -646.17%
Net Nonoperating Expense Percent (NNEP)		 -3.97% -5.23% -6.14% -6.64% -8.38% -8.71% -9.05% -12.24% -10.03% -14.70%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -25.96% -34.35% -42.89%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 137.05% 101.94% 107.31% 105.77% 95.26% 76.16% 215.10% 173.26% 321.15% 217.41%
R&D to Revenue		 184.81% 193.22% 259.02% 292.81% 251.52% 259.35% 695.27% 805.78% 1,199.36% 805.69%
Operating Expenses to Revenue		 321.86% 295.15% 366.32% 398.58% 346.78% 335.51% 910.37% 979.04% 1,520.79% 1,023.10%
Earnings before Interest and Taxes (EBIT)		 -13 -32 -70 -91 -106 -137 -270 -472 -512 -534
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -31 -67 -87 -97 -130 -256 -460 -529 -541
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 2.25 2.31 2.13 2.66 6.10 8.46 2.22 2.60 1.36
Price to Tangible Book Value (P/TBV)		 0.00 2.25 2.31 2.13 2.66 6.10 8.46 2.22 2.60 1.36
Price to Revenue (P/Rev)		 0.00 28.64 26.56 19.47 16.64 55.42 266.22 52.67 75.27 20.52
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 12.07 13.51 9.15 10.04 45.04 230.71 27.06 45.87 4.86
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 5.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 6.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.13 -1.26 -1.20 -1.13 -1.09 -1.11 -1.13 -1.10 -1.05 -1.03
Leverage Ratio		 1.22 1.37 1.32 1.25 1.24 1.27 1.26 1.24 1.23 1.30
Compound Leverage Factor		 1.22 1.35 1.28 1.17 1.16 1.25 1.26 1.24 1.15 1.26
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 131.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -31.48% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 3.63 5.54 4.52 5.41 12.42 19.94 4.58 4.29 -1.22
Noncontrolling Interest Sharing Ratio		 131.48% 31.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 7.26 9.15 11.32 8.01 8.12 9.60 6.11 9.61 8.67 5.77
Quick Ratio		 7.18 9.10 11.20 7.93 7.98 9.33 5.97 9.45 8.23 5.50
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 32 -72 -68 -96 -35 -129 -355 -443 -357
Operating Cash Flow to CapEx		 -69.03% 585.71% -646.87% -983.73% -1,519.58% -1,392.25% -1,764.11% -2,485.73% -2,817.92% -6,038.08%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.07 0.09 0.08 0.08 0.13 0.11 0.03 0.04 0.03 0.05
Accounts Receivable Turnover		 6.04 4.42 3.09 3.38 7.09 17.18 15.89 17.98 1.80 2.57
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.23 2.47 2.02 1.88 2.46 3.42 1.79 2.13 1.20 1.92
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 60.39 82.55 118.27 108.05 51.52 21.24 22.97 20.31 202.37 141.81
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 60.39 82.55 118.27 108.05 51.52 21.24 22.97 20.31 202.37 141.81
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -8.46 -63 -40 -36 -15 -75 -133 -99 -17 -34
Invested Capital Turnover		 -0.71 -0.46 -0.51 -0.80 -1.70 -1.29 -0.32 -0.45 -0.63 -2.29
Increase / (Decrease) in Invested Capital		 0.00 -55 23 3.94 22 -60 -58 34 83 -17
Enterprise Value (EV)		 0.00 199 353 279 433 2,612 7,626 1,410 1,664 282
Market Capitalization		 0.00 472 694 593 717 3,214 8,799 2,745 2,731 1,188
Book Value per Share		 ($87.25) $5.83 $8.33 $6.40 $5.52 $8.92 $13.98 $15.70 $11.73 $8.56
Tangible Book Value per Share		 ($87.25) $5.83 $8.33 $6.40 $5.52 $8.92 $13.98 $15.70 $11.73 $8.56
Total Capital		 67 210 301 278 270 527 1,040 1,236 1,050 872
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -76 -273 -341 -314 -284 -602 -1,174 -1,335 -1,067 -906
Capital Expenditures (CapEx)		 2.55 6.17 10 6.23 6.79 3.59 13 13 14 5.78
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.89 -22 -17 -30 -26 -45 -105 -102 -29 -73
Debt-free Net Working Capital (DFNWC)		 67 251 323 284 254 552 643 1,090 883 529
Net Working Capital (NWC)		 67 251 323 284 254 552 643 1,090 883 529
Net Nonoperating Expense (NNE)		 3.01 9.12 19 22 25 39 80 153 120 145
Net Nonoperating Obligations (NNO)		 -76 -273 -341 -314 -284 -602 -1,174 -1,335 -1,067 -906
Total Depreciation and Amortization (D&A)		 0.33 1.10 2.99 3.79 9.31 6.85 14 12 -17 -7.53
Debt-free, Cash-free Net Working Capital to Revenue		 -147.01% -136.46% -65.88% -97.44% -60.04% -77.78% -318.33% -196.43% -80.22% -125.27%
Debt-free Net Working Capital to Revenue		 1,107.40% 1,520.58% 1,238.55% 934.50% 588.93% 952.28% 1,946.78% 2,091.75% 2,434.52% 914.03%
Net Working Capital to Revenue		 1,107.40% 1,520.58% 1,238.55% 934.50% 588.93% 952.28% 1,946.78% 2,091.75% 2,434.52% 914.03%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($3.78) ($6.16) ($5.42) ($5.25)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 0.00 74.67M 76.97M 88.77M 98.85M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($3.78) ($6.16) ($5.42) ($5.25)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 0.00 74.67M 76.97M 88.77M 98.85M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($3.78) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 0.00 70.89M 88.02M 96.11M 103.52M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.39 -23 -49 -64 -74 -96 -187 -321 -361 -374
Normalized NOPAT Margin		 -155.30% -136.61% -186.42% -209.01% -172.74% -164.86% -567.26% -615.33% -994.17% -646.17%
Pre Tax Income Margin		 -221.86% -191.97% -258.62% -280.51% -230.25% -231.46% -817.05% -909.78% -1,316.22% -895.50%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -4.86% -8.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Intellia Therapeutics

This table displays calculated financial ratios and metrics derived from Intellia Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 84.15% 5.59% 12.03% -3.11% -9.60% -114.12% 129.53% -48.82% -24.02% 771.57% -42.54%
EBITDA Growth		 -62.80% -45.43% 18.37% -45.70% -23.41% -21.89% -1.92% -2.06% -7.33% 1.84% -2.16%
EBIT Growth		 -57.84% -38.47% 22.48% -35.06% -15.41% -17.72% -1.74% -4.29% -10.67% -0.18% -4.82%
NOPAT Growth		 -46.58% -36.90% 22.38% -34.62% -24.24% -27.07% -1.83% -5.07% -10.42% 2.46% -5.97%
Net Income Growth		 -58.04% -39.60% 29.79% -22.85% -7.94% -16.54% -4.18% -18.83% -11.04% 2.47% -6.42%
EPS Growth		 -53.61% -24.32% 40.31% -5.26% 7.38% -6.52% 4.27% -8.57% 2.90% 13.61% 1.79%
Operating Cash Flow Growth		 -20.77% -64.44% -37.00% -6.15% -29.11% -3.54% -10.37% 35.58% 16.32% 8.45% -23.43%
Free Cash Flow Firm Growth		 -219.23% -5,256.36% -526.44% -959.35% -129.78% -62.52% 24.36% 36.64% 51.04% 56.82% 39.93%
Invested Capital Growth		 3.44% 25.57% 71.23% 72.43% 85.47% 83.33% 131.84% 37.99% -96.89% -105.47% -61.83%
Revenue Q/Q Growth		 -5.45% 2.31% -7.12% 7.84% -11.78% -115.99% 1,609.39% -75.96% 30.96% 41.30% 29.15%
EBITDA Q/Q Growth		 -16.36% -3.21% -0.40% -20.83% 1.45% -1.95% 17.20% -21.00% -3.64% 6.76% 12.02%
EBIT Q/Q Growth		 -14.65% -1.38% 2.47% -19.16% 2.03% -3.40% 16.90% -22.15% -3.96% 6.40% 11.18%
NOPAT Q/Q Growth		 -7.35% -4.32% -1.70% -18.20% 0.93% -6.70% 18.51% -21.96% -4.12% 5.75% 11.46%
Net Income Q/Q Growth		 -12.47% -0.16% 9.07% -19.93% 1.18% -8.13% 18.71% -36.80% 7.66% 5.02% 11.30%
EPS Q/Q Growth		 -12.03% 7.38% 15.22% -19.66% 1.43% -6.52% 23.81% -35.71% 11.84% 5.22% 13.39%
Operating Cash Flow Q/Q Growth		 7.72% -14.44% -21.65% 17.38% -12.24% 8.21% -29.67% 51.78% -45.80% -0.42% -74.81%
Free Cash Flow Firm Q/Q Growth		 -378.07% -43.55% -52.95% -0.92% -3.70% -1.53% 28.81% 15.46% 19.87% 10.44% 0.99%
Invested Capital Q/Q Growth		 7.53% 1.50% 62.71% 18.84% 51.26% -13.04% 171.21% -258.07% -54.75% -17.97% 113.23%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -833.45% -840.77% -908.92% -1,018.46% -1,137.79% 0.00% -403.58% -2,031.06% -1,607.32% -1,060.62% -722.54%
Operating Margin		 -795.49% -811.07% -888.13% -973.47% -1,093.29% 0.00% -394.00% -1,998.61% -1,588.96% -1,059.86% -726.57%
EBIT Margin		 -854.36% -846.53% -888.93% -982.23% -1,090.82% 0.00% -394.00% -2,001.60% -1,588.96% -1,052.57% -723.85%
Profit (Net Income) Margin		 -853.53% -835.53% -818.07% -909.82% -1,019.21% 0.00% -371.30% -2,112.62% -1,489.54% -1,001.23% -687.61%
Tax Burden Percent		 100.00% 100.54% 100.00% 99.05% 100.24% 103.63% 100.00% 99.86% 100.00% 100.73% 100.40%
Interest Burden Percent		 99.90% 98.17% 92.03% 93.52% 93.21% 94.28% 94.24% 105.70% 93.74% 94.43% 94.62%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,843.90%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,840.60%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,815.10%
Return on Equity (ROE)		 -45.76% -41.67% -40.14% -45.68% -49.66% -42.10% -43.60% -49.02% -52.23% -54.00% -28.80%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,484.04% 0.00% 0.00% 0.00% -4,558.00%
Operating Return on Assets (OROA)		 -36.30% -31.35% -36.28% -42.81% -48.51% 0.00% -15.48% -73.17% -56.66% -48.89% -29.38%
Return on Assets (ROA)		 -36.27% -30.95% -33.39% -39.66% -45.33% 0.00% -14.59% -77.23% -53.11% -46.51% -27.90%
Return on Common Equity (ROCE)		 -45.76% -41.67% -40.14% -45.68% -49.66% -42.10% -43.60% -49.02% -52.23% -54.00% -28.80%
Return on Equity Simple (ROE_SIMPLE)		 -53.58% 0.00% -36.15% -41.04% -44.58% 0.00% -46.86% -52.40% -54.26% 0.00% -67.43%
Net Operating Profit after Tax (NOPAT)		 -74 -77 -78 -93 -92 -98 -80 -97 -101 -96 -85
NOPAT Margin		 -556.84% -567.75% -621.69% -681.43% -765.30% 0.00% -275.80% -1,399.02% -1,112.27% -741.91% -508.60%
Net Nonoperating Expense Percent (NNEP)		 -3.68% -2.90% -2.14% -2.92% -3.08% -2.85% -2.45% -4.67% -3.36% -3.38% -3.31%
Return On Investment Capital (ROIC_SIMPLE)		 - -6.24% - - - -9.32% - - - -10.95% -10.84%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 166.93% 174.07% 217.74% 225.48% 245.19% 0.00% 107.45% 456.99% 334.77% 252.01% 174.46%
R&D to Revenue		 728.56% 737.01% 770.40% 847.99% 948.10% 0.00% 386.55% 1,641.61% 1,354.19% 907.85% 652.11%
Operating Expenses to Revenue		 895.49% 909.24% 988.13% 1,073.47% 1,193.29% 0.00% 494.00% 2,098.61% 1,688.96% 1,159.86% 826.57%
Earnings before Interest and Taxes (EBIT)		 -113 -115 -112 -134 -131 -135 -114 -139 -145 -136 -120
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -111 -114 -115 -138 -136 -139 -117 -141 -146 -137 -120
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.16 2.22 2.75 3.25 2.70 2.60 2.38 2.22 2.17 1.36 0.94
Price to Tangible Book Value (P/TBV)		 5.16 2.22 2.75 3.25 2.70 2.60 2.38 2.22 2.17 1.36 0.94
Price to Revenue (P/Rev)		 82.75 52.67 61.35 67.77 54.05 75.27 46.83 46.97 48.45 20.52 16.15
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 122.02 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 64.74 27.06 38.38 46.37 33.73 45.87 27.36 25.44 25.44 4.86 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.11 -1.10 -1.08 -1.07 -1.06 -1.05 -1.01 -1.02 -1.02 -1.03 -0.99
Leverage Ratio		 1.25 1.24 1.22 1.23 1.25 1.23 1.20 1.21 1.21 1.30 1.24
Compound Leverage Factor		 1.25 1.21 1.12 1.15 1.17 1.16 1.13 1.28 1.13 1.22 1.17
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 8.97 5.35 7.91 8.86 6.90 5.25 5.14 3.94 3.75 -0.12 -0.93
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.55 9.61 9.32 9.41 9.72 8.67 9.03 7.21 6.73 5.77 4.90
Quick Ratio		 6.35 9.45 9.08 9.14 9.37 8.23 8.45 6.69 6.31 5.50 4.57
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -77 -111 -170 -172 -178 -181 -129 -109 -87 -78 -77
Operating Cash Flow to CapEx		 -1,853.34% -2,297.26% -2,853.03% -2,100.05% -2,340.28% -6,121.97% -4,814.92% -5,749.60% -6,633.07% -8,684.51% -20,262.59%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.04 0.04 0.04 0.04 0.04 0.03 0.04 0.04 0.04 0.05 0.04
Accounts Receivable Turnover		 15.78 17.98 15.95 13.41 9.85 1.80 2.55 5.29 5.62 2.57 1.94
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.21 2.13 1.93 1.80 1.71 1.20 1.65 1.45 1.38 1.92 1.59
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 23.13 20.31 22.89 27.22 37.07 202.37 143.40 69.02 65.00 141.81 187.95
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 23.13 20.31 22.89 27.22 37.07 202.37 143.40 69.02 65.00 141.81 187.95
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -101 -99 -37 -30 -15 -17 12 -19 -29 -34 4.50
Invested Capital Turnover		 -0.50 -0.45 -0.65 -0.76 -0.90 -0.63 -4.17 -1.89 -1.98 -2.29 5.59
Increase / (Decrease) in Invested Capital		 3.59 34 92 79 86 83 49 11 -14 -17 -7.29
Enterprise Value (EV)		 3,328 1,410 2,053 2,459 1,746 1,664 1,439 1,169 1,096 282 -39
Market Capitalization		 4,254 2,745 3,280 3,594 2,798 2,731 2,464 2,159 2,087 1,188 736
Book Value per Share		 $10.85 $15.70 $13.53 $12.54 $11.72 $11.73 $10.85 $10.07 $9.48 $8.56 $7.53
Tangible Book Value per Share		 $10.85 $15.70 $13.53 $12.54 $11.72 $11.73 $10.85 $10.07 $9.48 $8.56 $7.53
Total Capital		 825 1,236 1,191 1,105 1,037 1,050 1,036 971 963 872 780
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -926 -1,335 -1,228 -1,135 -1,052 -1,067 -1,024 -990 -991 -906 -775
Capital Expenditures (CapEx)		 4.24 3.91 3.83 4.30 4.33 1.52 2.51 1.01 1.28 0.98 0.74
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -100 -102 -73 -68 -53 -29 -5.16 -39 -53 -73 -65
Debt-free Net Working Capital (DFNWC)		 728 1,090 860 840 802 883 786 652 605 529 439
Net Working Capital (NWC)		 728 1,090 860 840 802 883 786 652 605 529 439
Net Nonoperating Expense (NNE)		 39 36 25 31 30 34 28 50 34 33 30
Net Nonoperating Obligations (NNO)		 -926 -1,335 -1,228 -1,135 -1,052 -1,067 -1,024 -990 -991 -906 -775
Total Depreciation and Amortization (D&A)		 2.77 0.78 -2.52 -4.93 -5.63 -3.84 -2.77 -2.05 -1.67 -1.04 0.22
Debt-free, Cash-free Net Working Capital to Revenue		 -195.28% -196.43% -136.99% -128.79% -102.86% -80.22% -9.81% -84.73% -122.77% -125.27% -142.53%
Debt-free Net Working Capital to Revenue		 1,415.93% 2,091.75% 1,608.77% 1,583.30% 1,548.42% 2,434.52% 1,494.43% 1,418.67% 1,404.68% 914.03% 962.93%
Net Working Capital to Revenue		 1,415.93% 2,091.75% 1,608.77% 1,583.30% 1,548.42% 2,434.52% 1,494.43% 1,418.67% 1,404.68% 914.03% 962.93%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.49) ($1.38) ($1.17) ($1.40) ($1.38) ($1.47) ($1.12) ($1.52) ($1.34) ($1.27) ($1.10)
Adjusted Weighted Average Basic Shares Outstanding		 76.05M 76.97M 87.77M 88.19M 88.65M 88.77M 95.50M 96.98M 101.00M 98.85M 103.50M
Adjusted Diluted Earnings per Share		 ($1.49) ($1.38) ($1.17) ($1.40) ($1.38) ($1.47) ($1.12) ($1.52) ($1.34) ($1.27) ($1.10)
Adjusted Weighted Average Diluted Shares Outstanding		 76.05M 76.97M 87.77M 88.19M 88.65M 88.77M 95.50M 96.98M 101.00M 98.85M 103.50M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 78.68M 88.02M 88.14M 88.49M 89.55M 96.11M 96.48M 101.58M 101.85M 103.52M 103.58M
Normalized Net Operating Profit after Tax (NOPAT)		 -74 -77 -78 -93 -92 -98 -80 -97 -101 -96 -85
Normalized NOPAT Margin		 -556.84% -567.75% -621.69% -681.43% -765.30% 0.00% -275.80% -1,399.02% -1,112.27% -741.91% -508.60%
Pre Tax Income Margin		 -853.53% -831.02% -818.07% -918.57% -1,016.74% 0.00% -371.30% -2,115.61% -1,489.54% -993.93% -684.89%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Intellia’s Q1 2025 results show sequential improvements in revenue and operating losses, but year-over-year headwinds and heavy cash burn remain significant challenges. Key takeaways:

  • Quarterly revenue rose 29.2% sequentially to $16.63 M in Q1 2025, marking a rebound from $12.87 M in Q4 2024.
  • Operating loss narrowed to $120.8 M in Q1 2025 from $136.4 M in Q4 2024, reflecting better cost control.
  • Net loss improved to $114.3 M (–$1.10 per share) in Q1 2025 versus $128.9 M (–$1.27) in Q4 2024.
  • Liquidity remains strong, with a current ratio of 4.90× and quick ratio of 4.57× at quarter end.
  • Intellia carried no debt on its balance sheet; net cash positions drove an enterprise value of –$39 M.
  • No equity was issued in Q1 2025 financing activities, leaving total shares outstanding unchanged.
  • R&D expense remains high at $108.4 M, representing 652% of quarterly revenue, underscoring the company’s heavy investment phase.
  • Revenue declined 42.5% year-over-year in Q1 2025 versus Q1 2024, highlighting tougher comparisons.
  • Net cash used in operating activities worsened to $149 M in Q1 2025 from $85.2 M in Q4 2024, signaling elevated cash burn.
  • Combined cash & short-term investments fell by $160 M to $503 M at quarter end, reducing the cash runway.
07/16/25 11:56 AMAI Generated. May Contain Errors.

Frequently Asked Questions About Intellia Therapeutics' Financials

When does Intellia Therapeutics' financial year end?

According to the most recent income statement we have on file, Intellia Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Intellia Therapeutics' net income changed over the last 9 years?

Intellia Therapeutics' net income appears to be on an upward trend, with a most recent value of -$519.02 million in 2024, rising from -$12.40 million in 2015. The previous period was -$481.19 million in 2023. See where experts think Intellia Therapeutics is headed by visiting Intellia Therapeutics' forecast page.

What is Intellia Therapeutics' operating income?
Intellia Therapeutics' total operating income in 2024 was -$534.26 million, based on the following breakdown:
  • Total Gross Profit: $57.88 million
  • Total Operating Expenses: $592.14 million
How has Intellia Therapeutics' revenue changed over the last 9 years?

Over the last 9 years, Intellia Therapeutics' total revenue changed from $6.04 million in 2015 to $57.88 million in 2024, a change of 857.6%.

How much debt does Intellia Therapeutics have?

Intellia Therapeutics' total liabilities were at $319.06 million at the end of 2024, a 27.2% increase from 2023, and a 2,058.3% increase since 2015.

How much cash does Intellia Therapeutics have?

In the past 9 years, Intellia Therapeutics' cash and equivalents has ranged from $57.23 million in 2019 to $523.51 million in 2022, and is currently $189.18 million as of their latest financial filing in 2024.

How has Intellia Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Intellia Therapeutics' book value per share changed from -87.25 in 2015 to 8.56 in 2024, a change of -109.8%.


Related Companies

This page (NASDAQ:NTLA) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners
Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...
Priority Gold | Sponsored
Utah’s New Oil Find
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...
Stansberry Research | Sponsored
Banks aren’t ready for this altcoin—are you?
The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...
Crypto 101 Media | Sponsored
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Revolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial Underway
Tiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!
Interactive Offers | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored